Rubicon Acquires 85% Stake in Arinna Lifesciences

Rubicon Research Limited disclosed its acquisition of an 85% stake in Arinna Lifesciences Limited, making it a subsidiary.
The transaction values Arinna at an enterprise value of INR 200 Crores, with a purchase consideration of approximately INR 175.92 Crores.
Arinna is a branded pharmaceutical marketing company focused on the CNS segment, reporting a turnover of INR 71.5 crores in FY25.
The acquisition is intended to leverage Rubicon's IP and chronic products portfolio for growth in the CNS therapeutic category.